Table 2 Demographics, clinical and treatment data of GBM patients (univariate analyses)
From: The immunohistochemical landscape of the VEGF family and its receptors in glioblastomas
N (%) | HR | CI 95% | P | |
|---|---|---|---|---|
Gender | ||||
Female | 26 (37.1) | 1 | ||
Male | 44 (62.9) | 1.26 | (0.75–2.11) | 0.39 |
Age (yr) | ||||
< 50 | 15 (21.4) | 1 | ||
≥ 50 | 55 (78.6) | 1.61 | (0.89–2.92) | 0.12 |
KPS (%) | ||||
< 70 | 20 (28.6) | 1 | ||
> 70 | 43 (61.4) | 0.51 | (0.29–0.89) | 0.02 |
NA | 7 (10.0) | |||
Neurosurgery (extent of resection) | ||||
Biopsy | 4 (5.7) | 1 | ||
Partial | 41 (58.6) | 0.42 | (0.13–1.41) | 0.16 |
Radical | 25 (35.7) | 0.24 | (0.17–0.57) | 0.02 |
Adjuvant treatment | ||||
Best supportive care | 21 (30.0) | 1 | ||
Only RT | 16 (22.9) | 0.52 | (0.26–1.05) | 0.07 |
RT and sequencing chemotherapy | 20 (28.6) | 0.32 | (0.17–0.62) | 0.001 |
RT concurrent with chemotherapy | 13 (18.6) | 0.30 | (0.14–0.63) | 0.002 |